Journal article
Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic
Abstract
BACKGROUND: In metastatic hormone sensitive prostate cancer (mHSPC), treatment intensification with either docetaxel or an androgen-receptor-axis targeted therapy (ARAT), added to androgen deprivation therapy (ADT) is the new standard of care. To better understand patterns of treatment intensification in Canada and specifically how it has been influenced by the COVID-19 pandemic, we conducted a national survey of genitourinary medical …
Authors
Stecca CE; Jiang DM; Veitch Z; Hotte SJ; Alimohamed N; Wood L; Sridhar SS
Journal
Clinical Genitourinary Cancer, Vol. 21, No. 2, pp. 273–277
Publisher
Elsevier
Publication Date
April 2023
DOI
10.1016/j.clgc.2022.11.020
ISSN
1558-7673